InDex Pharmaceuticals has received a conditional approval for continued listing on Nasdaq First North Growth Market after the reverse merger of Flerie
June 7, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") has today received a conditional approval from Nasdaq Stockholm ("Nasdaq") for continued listing of the Company's share on Nasdaq First North Growth Market. The Company has previously submitted an application for approval for continued listing as a part of the completion of the reverse merger of Flerie Invest AB.
Background
On May 20, 2024, InDex Pharmaceuticals entered into a conditional agreement to acquire all shares in Flerie Invest AB ("Flerie") (the “Transaction"). The Transaction constitutes a so-called reverse merger whereby Flerie becomes a wholly owned subsidiary of InDex Pharmaceuticals, which in connection with the Transaction changes its name to Flerie AB (“New Flerie”), and is conditional, inter alia, upon that the Company is approved for continued listing on Nasdaq First North Growth Market. Following the Transaction, the Company's operations will consist of the operations currently conducted by Flerie. In light of the substantial change of the business that the Transaction entails, InDex Pharmaceuticals has applied for approval from Nasdaq Stockholm for continued listing of the Company's share with the new business. In connection with the application for continued listing, the Company published a company description on May 27, 2024, containing information about, among other things, Flerie, InDex Pharmaceuticals and the Transaction.
Approval for continued listing on Nasdaq First North Growth Market
The approval is conditional upon the Company completing the Transaction, the distribution requirement for the Company's shares continuing to be met in accordance with the Nasdaq First North Growth Market Rulebook (the ‘Rulebook’) and Flerie updates its website in accordance with the Rulebook.
Admission to trading on Nasdaq Stockholm
In connection with the completion of the Transaction, the Company intends to carry out an uplisting from Nasdaq First North Growth Market to Nasdaq Stockholm. The Company will prepare and publish a prospectus for admission to trading of New Flerie’s share on Nasdaq Stockholm. The prospectus is intended to be approved by the Swedish Financial Supervisory Authority and published by the Company around June 26, 2024. The first day of trading on Nasdaq Stockholm is planned to take place around June 27, 2024.
For more information:
Jenny Sundqvist, CEO
Tel: +46 8 122 038 50
E-mail: jenny.sundqvist@indexpharma.com
Johan Giléus, CFO and Deputy CEO
Tel: +46 8 122 038 50
E-mail: johan.gileus@indexpharma.com
Ted Fjällman, CEO of Flerie
E-mail: contact@flerie.com
Publication
The information was submitted for publication, through the agency of the contact persons set out above at 16:30 CEST on June 7, 2024.
InDex Pharmaceuticals in brief
InDex Pharmaceuticals is based in Stockholm, Sweden. The Company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB is the Company’s Certified Adviser. For more information, please visit www.indexpharma.com.
Tags: